Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of “Moderate Buy” by Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $7.25.

Several research firms have weighed in on RGLS. Leerink Partnrs reiterated an “outperform” rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. StockNews.com initiated coverage on shares of Regulus Therapeutics in a research report on Tuesday, April 16th. They set a “sell” rating on the stock. SVB Leerink assumed coverage on Regulus Therapeutics in a report on Monday, March 18th. They issued an “outperform” rating and a $6.00 price target on the stock. Wells Fargo & Company boosted their price target on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 13th. Finally, Canaccord Genuity Group lowered their target price on Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, March 19th.

Institutional Investors Weigh In On Regulus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. lifted its holdings in shares of Regulus Therapeutics by 5.3% in the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 11,701 shares during the period. FMR LLC boosted its holdings in shares of Regulus Therapeutics by 32.4% in the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 716,000 shares in the last quarter. Finally, Vivo Capital LLC acquired a new stake in Regulus Therapeutics in the first quarter valued at approximately $14,400,000. 92.38% of the stock is owned by institutional investors.

Regulus Therapeutics Trading Down 8.3 %

Shares of RGLS opened at $2.43 on Tuesday. The firm has a market cap of $159.08 million, a PE ratio of -1.53 and a beta of 1.59. Regulus Therapeutics has a 1-year low of $1.08 and a 1-year high of $3.79. The firm has a fifty day simple moving average of $2.32 and a two-hundred day simple moving average of $1.69.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40). As a group, research analysts forecast that Regulus Therapeutics will post -0.52 EPS for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.